Exportar Publicação

A publicação pode ser exportada nos seguintes formatos: referência da APA (American Psychological Association), referência do IEEE (Institute of Electrical and Electronics Engineers), BibTeX e RIS.

Exportar Referência (APA) 
Mello-Sampayo, F. de., Vale, S. de S. & Camões, F. (2013). Substitutability between drugs, innovation and growth in the pharmaceutical industry. 10th EBES Conference Proceedings (pp. 13?28). EBES.
Exportar Referência (IEEE) 
F. D. Sampayo et al.,  "Substitutability between drugs, innovation and growth in the pharmaceutical industry", in 10th EBES Conf. Proc., Istanbul, EBES, 2013, pp. 13-28
Exportar BibTeX 
@inproceedings{sampayo2013_1789169169767,
	author = "Mello-Sampayo, F. de. and Vale, S. de S. and Camões, F.",
	title = "Substitutability between drugs, innovation and growth in the pharmaceutical industry",
	booktitle = "10th EBES Conference Proceedings",
	year = "2013",
	editor = "",
	volume = "",
	number = "",
	series = "",
	pages = "13-28",
	publisher = "EBES",
	address = "Istanbul",
	organization = "EBES",
	url = "https://ebesweb.org/proceedings/"
}
Exportar RIS 
TY  - CPAPER
TI  - Substitutability between drugs, innovation and growth in the pharmaceutical industry
T2  - 10th EBES Conference Proceedings
AU  - Mello-Sampayo, F. de.
AU  - Vale, S. de S.
AU  - Camões, F.
PY  - 2013
SP  - 13-28
CY  - Istanbul
UR  - https://ebesweb.org/proceedings/
AB  - This paper establishes a relationship between the elasticity of demand for pharmaceutical intermediates and the growth rate for these intermediates variety. We build a model that contains two sectors, one final good sector producing treatments, and one intermediate goods sector producing a differentiated input used in the final treatment. The effects on the medicaments varieties' growth rate of the introduction of a fiscal instrument over pharmaceutical producers' profits are discussed. When the fiscal instrument is a tax over intermediate firms' profits, R&D by firms in the pharmaceutical goods sector results in positive growth provided there is enough substitutability among intermediates assured by a patent system. Otherwise, a subsidy over pharmaceutical firms' profits should be considered to generate positive growth of innovation in medicaments.
ER  -